^
Association details:
| Biomarker: | AR overexpression |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | vosilasarm (EP0062) (Selective androgen receptor modulator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Computational modeling of androgen receptor (AR) and estrogen receptor as predictive biomarkers of response to AR agonists and antagonists
Published date:
11/17/2020
Excerpt:
We evaluated AR and ER expression levels among 68 samples with ER+ breast cancers...We developed preclinical models using AR and ER expression levels to predict AR-targeting drug response. The results support the use of RAD140 in AR high patients and those with an AR/ER ratio >3.10, and enzalutamide in AR high patients and those with an AR/ER ratio <0.42.
